Vir Biotechnology, Inc.
No SEC Form 4 filings for $VIR in the last 30 days.
See all $VIR insider activity →Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a20260805-q2ex991earningsr.htm EX-99.1 Document Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable H
Apnimed appointed Michael Kelly as CFO, replacing Ramzi Benamar, as it prepares for a potential commercial launch of AD109 for adults with obstructive sleep apnea. EnGene announced CFO Ryan Daws will depart July 15 after a planned ~50% workforce reduction. Other biopharma firms named new finance leaders, including Spruce Biosciences, Uniquity Bio, and Vir Biotechnology.
Vir Biotechnology shares (NASDAQ:VIR) fell 5.6% after CFO Jason O’Byrne announced his departure. The company appointed Brent Sabatini, Senior VP and Chief Accounting Officer, as interim principal financial officer effective July 23, with O’Byrne staying through Aug. 3. Vir said it will search for a new CFO.
Over the past 7 days, alphai's AI scored 1 news story mentioning VIR (Vir Biotechnology, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VIR coverage spans financial news, corporate actions and insider activity.
The 8-K adds actionable near-term catalysts via CHD Phase 3 timeline updates, ongoing VIR-5500 dose expansion, and cash runway support from Astellas payments.
Interim CFO appointment and planned CFO departure can raise transition risk, but the article does not cite accounting issues or financial stress.
CFO departure and interim finance leadership can raise near-term uncertainty around financial oversight and execution, aligning with the stock’s sharp drop.
Interim CFO appointment and CFO search can shift near-term financial reporting oversight and investor confidence, but no numbers or guidance are provided.
Leadership transition at the CFO level can affect near-term financial reporting continuity and investor confidence, but no operational or guidance changes were disclosed.
alphai scores every news story that mentions VIR with an AI model for sentiment and relevance, and aggregates insider trades from Vir Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a20260805-q2ex991earningsr.htm EX-99.1 Document Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable H
6 min readApnimed appointed Michael Kelly as CFO, replacing Ramzi Benamar, as it prepares for a potential commercial launch of AD109 for adults with obstructive sleep apnea. EnGene announced CFO Ryan Daws will depart July 15 after a planned ~50% workforce reduction. Other biopharma firms named new finance leaders, including Spruce Biosciences, Uniquity Bio, and Vir Biotechnology.
4 min readVir Biotechnology shares (NASDAQ:VIR) fell 5.6% after CFO Jason O’Byrne announced his departure. The company appointed Brent Sabatini, Senior VP and Chief Accounting Officer, as interim principal financial officer effective July 23, with O’Byrne staying through Aug. 3. Vir said it will search for a new CFO.
3 min readVir Biotechnology Inc. appointed Brent Sabatini, its SVP and Chief Accounting Officer, as Interim Principal Financial Officer after Jason O’Byrne left to pursue another opportunity. Vir said it has started a search for a permanent CFO. The company cited Sabatini’s role in prior financing and business development efforts.
2 min readVir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. vir-20260720 FALSE 0001706431 0001706431 2026-07-20 2026-07-20 0001706431 exch:XNAS 2026-07-20 2026-07-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REP
2 min readVir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. vir-20260609 FALSE 0001706431 0001706431 2026-06-09 2026-06-09 0001706431 exch:XNAS 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REP
2 min readNapolitano Janet sold 3,200 shares of Vir Biotechnology, Inc. (VIR) at $9.45 on 2026-06-01 under a Rule 10b5-1 trading plan.
1 min readSabatini Brent (SVP, Chief Accounting Officer) sold 379 shares of Vir Biotechnology, Inc. (VIR) at $9.45 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readVanguard Group Inc. decreased its holding in Vir Biotechnology, Inc. by 2.0% in the fourth quarter but remains the largest disclosed shareholder with 12.55 million shares. Despite a weak latest quarter with a significant EPS loss and revenue miss, analysts maintain a "Moderate Buy" consensus rating with a target price of $20.25. Insider selling activity also occurred recently, with the stock trading around $9.09.
3 min readVir Biotechnology's President & CEO, Marianne De Backer, has restructured her common stock holdings, reclassifying a total of 467,064 shares into a family trust for tax and estate planning. This transaction, reported via Form 4, involves two entries of 233,532 shares each, shifting ownership without consideration rather than a market buy or sell. Following the changes, she holds 714,613 direct shares and 286,650 indirect shares through the Ureel-De Backer Family Trust.
2 min read
